Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes

• Published in: The Journal of immunology (1950) Vol. 194; no. 7; pp. 3246 - 3258
• Main Authors: Carvallo, Loreto, Lopez, Lillie, Che, Fa-Yun, Lim, Jihyeon, Eugenin, Eliseo A, Williams, Dionna W, Nieves, Edward, Calderon, Tina M, Madrid-Aliste, Carlos, Fiser, Andras, Weiss, Louis, Angeletti, Ruth Hogue, Berman, Joan W
• Format: Journal Article
• Language: English
• Published: United States 01.04.2015
• Subjects: Analgesics, Opioid - pharmacology; Buprenorphine - pharmacology; Cell Adhesion Molecules - metabolism; Cell Membrane - drug effects; Cell Membrane - metabolism; Chemokine CCL2 - metabolism; Chemotaxis, Leukocyte - drug effects; Chemotaxis, Leukocyte - immunology; Human immunodeficiency virus; Humans; Monocytes - drug effects; Monocytes - immunology; Monocytes - metabolism; p38 Mitogen-Activated Protein Kinases - metabolism; Phenotype; Phosphopeptides - metabolism; Phosphorylation; Proteome; Proteomics; Receptors, CCR2 - metabolism; Receptors, Cell Surface - metabolism; Receptors, Opioid - metabolism
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.1302647

Despite successful combined antiretroviral therapy, ∼ 60% of HIV-infected people exhibit HIV-associated neurocognitive disorders (HAND). CCL2 is elevated in the CNS of infected people with HAND and mediates monocyte influx into the CNS, which is critical in neuroAIDS. Many HIV-infected opiate abusers have increased neuroinflammation that may augment HAND. Buprenorphine is used to treat opiate addiction. However, there are few studies that examine its impact on HIV neuropathogenesis. We show that buprenorphine reduces the chemotactic phenotype of monocytes. Buprenorphine decreases the formation of membrane projections in response to CCL2. It also decreases CCL2-induced chemotaxis and mediates a delay in reinsertion of the CCL2 receptor, CCR2, into the cell membrane after CCL2-mediated receptor internalization, suggesting a mechanism of action of buprenorphine. Signaling pathways in CCL2-induced migration include increased phosphorylation of p38 MAPK and of the junctional protein JAM-A. We show that buprenorphine decreases these phosphorylations in CCL2-treated monocytes. Using DAMGO, CTAP, and Nor-BNI, we demonstrate that the effect of buprenorphine on CCL2 signaling is opioid receptor mediated. To identify additional potential mechanisms by which buprenorphine inhibits CCL2-induced monocyte migration, we performed proteomic analyses to characterize additional proteins in monocytes whose phosphorylation after CCL2 treatment was inhibited by buprenorphine. Leukosialin and S100A9 were identified and had not been shown previously to be involved in monocyte migration. We propose that buprenorphine limits CCL2-mediated monocyte transmigration into the CNS, thereby reducing neuroinflammation characteristic of HAND. Our findings underscore the use of buprenorphine as a therapeutic for neuroinflammation as well as for addiction.